PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number

28 + 110

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

10/627,372 Filing Date July 24, 2003 First Named Inventor Harrihar A. PERSHADSINGH Art Unit Not Yet Assigned **Examiner Name** Not Yet Assigned Attorney Docket Number 421842000400

Total Number	r of Pages in This Submiss	Refs.	421842000400					
ENCLOSURES (Check all that apply)								
Fee Transr	nittal Form	Drawing(s)	After Allowance Communication to Group					
Fee /	Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences					
Amendmer	nt/Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)					
After	Final	Petition to Convert to a Provisional Application	Proprietary Information					
Affida	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter					
Extension	of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please identify below):					
Express At	pandonment Request	Request for Refund	Form PTO-1449 (12 pages in duplicate)					
x Information (3 pages)	Disclosure Statement	CD, Number of CD(s)	References (110) Return receipt postcard					
Certified Co	opy of Priority s)							
	to Missing Parts/ Application	Remarks						
	onse to Missing Parts r 37 CFR 1.52 or 1.53							
			- A05115					
	SIGNAT	URE OF APPLICANT, ATTORNEY, O	R AGENT					
Firm or	MORRISON & FOE		25226					
individual name	Individual name Shantanu Basu - 43,318							
Signature	Thanlur	Lay						
Date	November 21, 2003							
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.								

pa-841125

Dated: November 21, 2003



CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

Thereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on November 21, 2003.

Mutina Placed

Martina Placid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Harrihar A. PERSHADSINGH

Serial No.: 10/627,372

Filing Date: July 24, 2003

For: NOVEL PPAR LIGANDS THAT DO

NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART

FAILURE

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. §1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references numbered 1 through 109 are not submitted. Copies of foreign patent documents and non-patent

literature are submitted herewith in accordance with 37 C.F.R. § 1.98 (a)(2). The Examiner is requested to make these documents of record.

	This In	formation Disclosure Statement is submitted:
	With	the application; accordingly, no fee or separate requirements are required.
	Befor	e the mailing of a first Office Action after the filing of a Request for Continued
	Exam	ination under § 1.114.
\boxtimes	Withi	n three months of the application filing date or before mailing of a first Office
	Actio	n on the merits; accordingly, no fee or separate requirements are required.
	After	receipt of a first Office Action on the merits but before mailing of a final Office
	Actio	n or Notice of Allowance.
		A fee is required. A check in the amount of is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee
		is believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does

not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 421842000400. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: November 21, 2003

Respectfully submitted,

By:

Shantanu Basu

Registration No. 43,318

Morrison & Foerster LLP 755 Page Mill Road

Palo Alto, California 94304-1018

Telephone: (650) 813-5995 Facsimile: (650) 494-0792

_	DA	10 1	1 4 4 1
Form	\mathbf{P}	()_	12/2/14
I OIIII	1 1	O-1	しててノ

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

NOV 2 4 2003

(Use several sheets if necessary)

	Dilect I Of 12						
Docket Number 421842000400	Application Number 10/627,372						
Applicant							
Harrihar A. PERSHADSINGH							
Filing Date July 24, 2003	Group Art Unit Not Yet Assigned						

U.S. PATENT DOCUMENTS

Mailing Date November 21, 2003

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/15/2000	RE 36,575	Meguro et al.			
	2.	07/07/1992	5,128,356	Naka et al.			
	3.	11/10/1992	5,162,326	Naka et al.			
	4.	03/23/1993	5,196,444	Naka et al.			
	5.	09/07/1993	5,243,054	Naka et al.			
	6.	10/05/1993	5,250,554	Naka et al.			
	7.	02/08/1994	5,284,661	Morimoto et al.			
	8.	07/12/1994	5,328,919	Naka et al.			
	9.	10/11/1994	5,354,766	Naka et al.			,
	10.	02/14/1995	5,389,641	Naka et al.			
	11.	03/28/1995	5,401,764	Naka et al.			
···	12.	10/31/1995	5,463,073	Takehiko et al.		·	
	13.	03/05/1996	5,496,835	Kubo et al.			1
	14.	03/19/1996	5,500,427	Kubo et al.			1, 10 90191
	15.	04/09/1996	5,506,245	Regnier et al.			
	16.	07/30/1996	5,541,229	Narr et al.			
.,	17.	10/15/1996	5,565,469	Mihm et al.			
	18.	12/10/1996	5,583,141	Naka et al.			
	19.	12/24/1996	5,587,393	Narr et al.			
	20.	01/07/1997	5,591,762	Hauel et al.			
	21.	01/14/1997	5,594,003	Hauel et al.			
	22.	02/11/1997	5,602,127	Hauel et al.			
	23.	03/25/1997	5,614,519	Hauel et al.			
	24.	06/17/1997	5,639,773	Kubo et al.			
	25.	09/02/1997	5,663,186	Nelson et al.			
	26.	09/02/1997	5,663,187	Nelson et al.	Ì		
	27.	11/04/1997	5,684,029	Narr et al.			-

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Docket Number 421842000400 Application Number 10/627,372 Form PTO-1449 Applicant INFORMATION DISCLOSURE CITATION Harrihar A. PERSHADSINGH IN AN APPLICATION (Use several sheets if necessary) Filing Date July 24, 2003 Group Art Unit Not Yet Assigned Mailing Date November 21, 2003 BADENAS 28. 12/02/1997 | 5,693,651 Nomura et al. 29. 12/30/1997 5,703,110 Naka et al. 30. 01/06/1998 5,705,517 Naka et al. 31. 04/07/1998 5,736,555 Naka et al. 32. 04/21/1998 5,741,803 Pool et al. 33. 09/01/1998 5,801,173 Lohray et al. 34. Ogawa et al. 09/22/1998 5,811,439 35. 10/06/1998 5,817,075 Giungo 36. Kurtz et al. 10/20/1998 5,824,694 37. 10/27/1998 Haigh et al. 5,827,865 38. Fujita et al. 11/10/1998 5,834,501 39. 12/01/1998 Yan 5,843,172 40. 12/01/1998 5,843,970 Pershadsingh et al. 41. 12/08/1998 5,847,008 Doebber et al. 42. 01/12/1999 5,859,051 Adams et al. 43. 01/26/1999 Narr et al. 5,864,043 44. Giungo et al. 02/09/1999 5,868,728 45. 02/09/1999 Haigh et al. 5,869,495 03/16/1999 46. Naka et al. 5,883,111 47. 03/23/1999 5,885,997 Lohray et al. 48. 03/23/1999 Fujita et al. 5,886,014 49. 03/30/1999 5,889,025 Lohray et al. 50. 5,889,032 03/30/1999 Lohray et al. 51. 05/11/1999 5,902,726 Kliewer et al. 52. 06/08/1999 5,910,592 Pool et al. 53. 07/06/1999 5,919,782 Lohray et al. 54. Kallam et al. 07/20/1999 5,925,656 55. Sohda et al. 08/03/1999 5,932,601 56. Evans et al. 08/17/1999 5,939,442 57. Ikeda et al. 09/14/1999 5,952,356 DATE CONSIDERED: **EXAMINER:**

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92) pa- 820933

Form PTO-1449				Application Number 10/027,372					
O THE ORI						Applicant Harrihar A. PERSHADSINGH			
2 2003		e several sheets if r			Fi	ling Date July 24, 2003		Group Art Uni	it Not Yet Assigned
NOV 2 4 2003					М	ailing Date November 21, 20	003		
10.00									
	58.	09/14/1999	5,952,509	Saito	et	al.			
	59.	09/28/1999	5,958,942	Taka	tan	i et al.			
	60.	09/28/1999	5,958,961	Inada	ı et	al.			
	61.	10/05/1999	5,962,470	Fujita	a et	t al.			
	62.	10/05/1999	5,962,491	Naka	et	al.			
	63.	10/12/1999	5,965,584	Ikeda	et	al.			
	64.	10/19/1999	5,968,589	Mura	ka	mi			
	65.	10/26/1999	5,972,959	Yana	gis	sawa et al.			
	66.	10/26/1999	5,972,970	Sohd	a e	t al.			
	67.	11/02/1999	5,977,365	Fujita	a e	t al.			
	68.	11/16/1999	5,985,884	Lohr	ay	et al.			
	69.	11/23/1999	5,990,139	Yanc	et	al.			
	70.	12/21/1999	6,004,989	Naka	et	al.			
	71.	12/28/1999	6,008,237	Saho	o e	et al.			
	72.	01/04/2000	6,011,031	Lohr	ay	et al.			
	73.	01/04/2000	6,011,036	Lohr	ay	et al.			
	74.	02/01/2000	6,020,382	Doeb	be	r et al.			
	75.	02/08/2000	6,022,897	Evan	s e	t al.			
	76.	02/22/2000	6,028,088	Persl	nad	singh et al.			
	77.	07/11/2000	6,087,384	Mats	ui (et al.			
	78.	07/11/2000	6,087,385	Persl	nad	singh et al.			
	79.	07/18/2000	6,090,836	Adar	ns	et al.			
	80.	07/18/2000	6,090,839	Adar	ns	et al.			
	81.	08/08/2000	6,100,252	Naka	et	al.			
	82.	08/08/2000	6,100,403	Saito	et	al.			
	83.	08/15/2000	6,103,742	Ikeda	ı et	t al.			
	84.	09/05/2000	6,113,907	Khw	aja	et al.			
	85.	09/12/2000	6,117,893	Fujit	a e	t al.			
	86.	11/21/2000	6,150,371	Fujiv	var	a et al.			
	87.	12/12/2000	6,160,000	Adar	ns	et al.			
EXAMIN	ER:				T	DATE CONSIDER	RED:		

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92) pa- 820933

Form PTO-1449				Docket Number 421842000400 Application Number		ber 10/627,37	72		
NIOR MATION DISCLOSURE CITATION				Applicant					
	A. W	AN APPLIC	ATION	į	Нагті	har A. PER	SHADSINGH		
NOV 242		e several sheets if r	aecessary)		Filing Date July 24, 2003		Group Art Unit N	Not Yet Assign	ned
RADEMA				,	Mailing Date November 21, 20	03		W	
Rannah	RKOK								
SUDERIN	88.	03/13/2001	6,200,995	De L	a Brouse-Elwood et al.				
	89.	05/08/2001	6,228,874	Inada	et al.			:-	
	90.	05/15/2001	6,232,334	Naka	et al.				
	91.	12/11/2001	6,329,415	Cirill	o et al.				
	92.	12/25/2001	6,333,325	Cirill	o et'al.		'		
	93.	02/19/2002	6,348,481	Inada	et al.				
	94.	03/05/2002	6,353,011	Persh	nadsingh				
	95.	03/12/2002	6,355,808	Naka	et al.				
	96.	03/19/2002	6,358,945	Breit	felder et al.				
	97.	04/09/2002	6,369,098	Persh	nadsingh				-
	98.	04/16/2002	6,372,773	Rega	n				
	99.	07/02/2002	6,414,002	Chen	g et al.				
	100.	07/02/2002	6,414,008	Haue	l et al.				
· · · · · · · · · · · · · · · · · · ·	101.	07/16/2002	6,420,405	Inada	et al.				
	102.	08/13/2002	6,432,993	Fujita	a et al.				
	103.	08/13/2002	6,432,996	Tamı	ıra et al.				
	104.	09/17/2002	6,451,832	Ries	et al.				
-	105.	10/22/2002	6,468,996	Jeppe	esen et al.				
	106.	10/22/2002	6,469,039	Haue	el et al.				-
	107.	11/05/2002	6,476,023	Cirill	lo et al.			-	
	108.	11/12/2002	6,479,524	Priep	ke et al.				
	109.	11/26/2002	6,486,188		rsen et al.				
	Ref.	Date	Document No.		Country	Class	Subclass	Transl	ation
	No.							YES	NO
	110.	07/17/1997	WO 97/25042	WIP	0				
	111.	08/07/1997	WO 97/28137	WIP	0				
	112.	02/12/1998	WO 98/05331	WIP	0				
J_ _	113.	12/23/1998	WO 98/57941 .	WIP	0				
	-114.	12/09/1999	WO 99/62870	WIP	0				
EXAMI	JED.				DATE CONSIDER	ED:			
EAAWIII	VER.		to at all		Ditt Consider				
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in									

conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449			Docket Number 421842000400)	Application Nur	mber 10/627,	372		
PRESENTATION DISCLOSURE CITATION			Applicant						
/ O * * IN AN APPLICATION			Harrihar A. PERSHADSINGH						
NOV 2 4 20		se several sheets if r	necessary)		Filing Date July 24, 2003		Group Art Unit	Not Yet Assi	gned
3 101 2 7 20	3				Mailing Date November 21, 20	003			
E.	188								
RADEMAN	<u> 115.</u>	12/09/1999	WO 99/62871	WIP	0				
11	116.	12/09/1999	WO 99/62872	WIP	0				
	117.	07/27/2000	WO 00/27832	WIP	0				
1	118.	01/04/2001	WO 01/00603	WIP	0				
~~	119.	02/22/2001	WO 01/12612 ·	WIP	O ·				
4	120.	03/29/2001	WO 01/21602	WIP	0				
	121.	05/17/2001	WO 01/34094	WIP	0				
	122.	10/03/2002	WO 02/076177	WIP	0				
	•								
	Ref.	Title					<u>-</u>		
	No.								
	123.				ning and Expression of				
				Janua	ry 14, 1995, located at <	http://w	ww.ncbi.nlm	.nih.gov>	last
	124.	visited on September 24, 2003. GenBank Accession No. L02932, "cDNA Cloning, Chromosomal Mapping, and Functional							
_	124.				ome Proliferator Activat				6, 1993,
					ov> last visited on Septe				
	125.				lation and Characterizat			eceptor: A	\
· -					nily" created on June 12, sited on September 24, 2		cated at		
	126.				e Development of Seque		ged Sites for	Human	
-	120.				, 1993, located at http://				visited
		on Septembe							
į	127.				ntification of Nuclear R				
į				_	er Motif Sequences" cresited on September 24, 2		October 16, 1	1993, loca	ited at
	128.	 			man and Rat TR4 Orpha		tors Specify	a Subclas	s of the
	120.				on September 15, 1994			a Suocias	3 Of the
					sited on September 24,				
	129.				New Orphan Member of			e Recepto	or
_	•	Superfamily Closely Related to Rev-Erb" created on May 8, 1995, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.							
	130.	 			lation of the Human Per		Proliferator	Activated	·
	150.								
		Receptor Gamma cDNA: Expression in Hematopoietic Cells and Chromosomal Mapping" created on December 26, 2001, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.							
EXAMIN	NER:				DATE CONSIDER	RED:			
					on conforms with MPEP 609 next communication to applica		ine through the	citation if n	ot in
			. ,						

Form PTO-1449 ^D		Docket Number 421842000400	Application Number 10/627,372			
POFORMATION DISCLOSURE CITATION		Applicant				
N AN APPLICATION		Harrihar A. PERSHADSINGH				
NOV 2 4 2003 E		Filing Date July 24, 2003	Group Art Unit Not Yet Assigned			
- NOT 2-12			Mailing Date November 21, 2003			
	av. Si					
MADEM	131.	GenBank Accession No. M24748, "Ch Coexpressed with Other Thyroid Horn located at http://www.ncbi.nlm.nih.go	none Receptors in Several Tissue	es" created on May 9, 1995,		
-	132.	GenBank Accession No. M24857, "A on November 8, 1994, located at http://doi.org/10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-10.2016/j.jep-				
	133.	GenBank Accession No. M24898, "Tw Binding Capacities are Transcribed fro on November 7, 1994, located at <a created<="" href="https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://example.com/https://exam</td><td>om Opposite DNA Strands of the</td><td>Same Genetic Locus" td="">				
_	134.	GenBank Accession No. M26747, "Hu Members of a New Superfamily of Enl http://www.ncbi.nlm.nih.gov last vis	hancer Binding Proteins" created			
لمد	135.	GenBank Accession No. M29960, "Molecular Cloning of New Human TR2 Receptors: A Class of Steroid Receptor with Multiple Ligand-Binding Domains" created on August 3, 1993, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.				
_	136.	GenBank Accession No. M64497, "Regulation of the Apolipoprotein AI Gene by ARP-1, a Novel Member of the Steroid Receptor Superfamily" created on January 31, 1996, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.				
_	137.	GenBank Accession No. M81385, "Ex Homologue-1 as a Potential Steroidoge http://www.ncbi.nlm.nih.gov > last vi	enic Factor in Rat Ovary" create			
	138.	GenBank Accession No. M84820, "Pu with which RAR or TR Heterodimeriz 1995, located at http://www.ncbi.nlm	es to Bind Target Sequences Eff	iciently" created on January 9,		
•	139.	GenBank Accession No. S65876, "Cha Key Regulator of Steroid Hydroxylase http://www.ncbi.nlm.nih.gov > last vi	Gene Expression" created on M			
_	140.	GenBank Accession No. S77482, "The Expressed in the Developing Forebrair http://www.ncbi.nlm.nih.gov last visus of the control of	n" created on September 27, 199			
	141.	GenBank Accession No. U10375, "Diff Peroxisome Proliferator-Activated Rec http://www.ncbi.nlm.nih.gov > last vi	ceptors" created on July 22, 1994			
	142.					
GenBank Accession No. U12767, "The Isolation and Characterization of MINOR, a Novel Mito Inducible Nuclear Orphan Receptor" created on June 17, 1996, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.						
EXAMI	NER:		DATE CONSIDERED:			
	• EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.					

Form PTO-1449			Docket Number 421842000400	Application Number 10/627,372				
NECEMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Harrihar A. PERSHADSINGH						
MMU 2 4 2002 (Use several sheets if necessary)		se several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned				
NOV 2 4 2003			Mailing Date November 21, 2003					
	" Q.E.							
MADENIA	144.	GenBank Accession No. U14534, "Ub Activation by Retinoic Acid and Thyro http://www.ncbi.nlm.nih.gov > last vis	oid Hormone Receptors" created					
~	145.	GenBank Accession No. U14666, "Clo Germ Cell Development" created on M visited on September 24, 2003.						
1	146.	GenBank Accession No. U16997, "RO Subfamily that is Highly Expressed in http://www.ncbi.nlm.nih.gov last vis	Skeletal Muscle" created on Apr					
7	147.	GenBank Accession No. U18374, "Ide Metabolites" created on June 21, 1995, September 24, 2003.						
->	148.	GenBank Accession No. U38480, "Characterization of Three RXR Genes that Mediate the Action of 9-cis Retinoic Acid" created on November 8, 1995, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.						
	149.	GenBank Accession No. X06614, "A Transferable Silencing Domain is Present in the Thyroid Hormone Receptor, in the v-erbA Oncogene Product and in the Retinoic Acid Receptor" created on September 12, 1993, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.						
	150.	GenBank Accession No. X12794, "Ide Molecular Cloning: The Gene Product 25, 1997, located at http://www.ncbi.	s of the Two are Highly Related	to Each Other" created on June				
1	151.	GenBank Accession No. X12795, "Ide Molecular Cloning: The Gene Product 25, 1997, located at http://www.ncbi.	s of the Two are Highly Related	to Each Other" created on June				
-	152.	GenBank Accession No. X51416, "Ide created on April 3, 1997, located at <h 2003.<="" td=""><td></td><td></td></h>						
	153.	GenBank Accession No. X51417, "Identification of a New Class of Steroid Hormone Receptors" created on February 10, 1999, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.						
-	154.	GenBank Accession No. X52773, "Nu Pathway" created on September 12, 19 September 24, 2003.						
	155. GenBank Accession No. X75163, "A Novel Nuclear Receptor Superfamily Member in Xenopus That Associates with RXR, and Shares Extensive Sequence Similarity to the Mammalian Vitamin D3 Receptor" created on February 2, 1994, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.							
EXAMIN	IER:		DATE CONSIDERED:					
		EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.						

Form PTO-1449			Docket Number 421842000400	Application Number 10/627,372			
INFORMATION DISCLOSURE CITATION		ON DISCLOSURE CITATION	Applicant				
N AN APPLICATION			Harrihar A. PERSHADSINGH				
NOV 2 4 2003 (Use several sheets if necessary)			Filing Date July 24, 2003	Group Art Unit Not Yet Assigned			
			Mailing Date November 21, 2003				
PADEMA			<u></u>				
)	156.	GenBank Accession No. X75918, "NO to the Steroid/Thyroid Hormone Receptor Chttp://www.ncbi.nlm.nih.gov> last vi	otor NAK1/TR3" created on Jan				
خ	157.	GenBank Accession No. X76930, "Clo Hepatocyte Nuclear Factor 4 Indicate to November 8, 1994, located at <a created="" href="http://v</td><td>the Presence of Two Isoforms in</td><td>Human Liver" on<="" td="">					
^	158.	GenBank Accession No. Y00291, "A I Inappropriately Expressed in Human F at http://www.ncbi.nlm.nih.gov last	Iepatocellular Carcinoma" creat	ed on January 14, 1991, located			
سے	159.	GenBank Accession No. Z49826, "Hu Distinct and Differentially Expressed (http://www.ncbi.nlm.nih.gov last vi	Genes" created on September 6,				
 -	160.	Adams, A.D. et al. (2003). "Amphipat Agonists," <i>Bioorganic & Medicinal Ci</i>		zoles; Human PPaR γ , δ and α			
_	161.	Alberti, K.G.M.M. and Zimmet, P.Z. (1998). "Definition, Diagonisis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus Provisional Report of a WHO Consultation," <i>Diabet. Med.</i> 15:539-553.					
4 -	162.	Almansa, C. et al. (1996). "Diphenylp Antagonists," J. Med. Chem. 39:2197-		ective Angiotensin II			
	163.	Almansa, C. et al. (1997). "Synthesis a AT ₁ Selective Angiotensin II Receptor <i>Chem.</i> 40:547-558.					
	164.	American Diabetes Association (2002) 25(4):742-749.). "The Prevention or Delay of T	ype 2 Diabetes," Diabetes Care			
	165.	American Medical Association. (2001) Cholesterol Education Program (NCE) High Blood Cholesterol in Adults (Ad	P) Expert Panel on Detection, Ev	valuation, and Treatment of			
	166.	American Medical Association. (2002). "Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)," JAMA 288(23):2981-2997.					
	Ashton, W.T. et al. (1994). "Triazolinone Biphenylsulfonamide Derivatives as Orally Active Angiotensin II Antagonists with Potent AT ₁ Receptor Affinity and Enhanced AT ₂ Affinity," J. Med. Chem. 37:2808-2824.						
	168.	Atwal, K.S. et al. (1992). "Dihydropyr 35:4751-4763.	rimidine Angiotensin II Receptor	r Antagonists," J. Med. Chem.			
EXAMIN	NER:		DATE CONSIDERED:				
		al if citation considered, whether or not the citati		line through the citation if not in			

Form PTO-1449		Docket Number 421842000400	Application Number 10/627,372			
INFORMATION DISCLOSURE CITATION		Applicant	<u></u>			
IN AN APPLICATION		Harrihar A. PERSHADSINGH				
NOV 2 4 2003 (Use several sheets if necessary)		Filing Date July 24, 2003	Group Art Unit Not Yet Assigned			
		Mailing Date November 21, 2003				
MADEMAN 169.						
169.	Bernhart, C.A. et al. (1993). "A New S AT ₁ Angiotensin II Receptor Antagoni					
170.	Bernobich, E. et al. (2002). "The Role Therapeutic Implications," <i>Drugs</i> 62(9)		ardiac Glucose Homeostasis:			
171.	Blankley, C.J. et al. (1991). "Synthesis Non-Peptide Angiotensin II Receptor I Chem. 34:3248-3260.					
172.	Brasier, A.R. et al. (2000). "Angiotensin II Induces Gene Transcription Through Cell-Type-Dependent Effects on the Nuclear Factor-κB (NF-κB) Transcription Factor," <i>Mol. Cell. Biochem.</i> 212:155-169.					
173.	Brooks, D.A. et al. (2001). "Design and Synthesis of 2-Methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic Acids: A New Class of Dual PPARα/γ Agonists," <i>J. Med. Chem.</i> 44:2061-2064.					
174.	Bühlmayer, P. et al. (1991). "Nonpeptidic Angiotensin II Antagonists: Synthesis and in Vitro Activity of a Series of Novel Naphthalene and Tetrahydronaphthalene Derivatives," <i>J. Med. Chem.</i> 34:3105-3114.					
175.	Carini, D.J. et al. (1991). "Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylylmethyl)Imidazoles as Potent, Orally Active Antihypertensives," J. Med. Chem. 34:2525-2547.					
176.	Cronet, P. et al. (2001). "Structure of the 242; Ligand Selectivity and Agonist A					
177.	Dahlöf, B. et al. (2002). "Cardiovascul Endpoint Reduction in Hypertension S <i>Lancet</i> 359:995-1003.					
178.	Danforth, E. Jr. (2000). "Failure of AdNat. Genet. 26:13.	pocyte Differentiation Causes	Гуре II Diabetes Mellitus?"			
179.	De, B. et al. (1992). "Discovery of a N Antagonists," J. Med. Chem. 35:3714-		n-Peptide Angiotensin II			
180.	Dhanoa, D.S. et al. (1993). "(Dipropyl) Angiotensin II Receptor Antagonists,"		New Generation of Nonpeptide			
181.	Easthope, S.E. and Jarvis, B. (2002). "George Hypertension," <i>Drugs</i> 62(8):1253-1287		te of its Use in Essential			
182. Ellingboe, J.W. et al. (1998). "Metabolites of the Angiotensin II Antagonist Tasosartan: The Importance of a Second Acidic Group," <i>J. Med. Chem.</i> 41:4251-4260.						
		·				
EXAMINER:		DATE CONSIDERED:				
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.					

10111110-1 44 2			Docket Number 421842000400	Application Number 10/627,372		
E ELECTIVITATION DISCLOSURE CITATION			Applicant			
IN AN APPLICATION			Harrihar A. Pl	ERSHADSINGH		
NOV 2 4 2003	E CU	se several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned		
			Mailing Date November 21, 2003			
Or all	3 ⁵ .					
MADEMARY	183.	Epstein, M. (2002). "Angiotensin II Receptor Antagonists: Current Status" Chapter 17 In Angiotensin II Receptor Antagonists Epstein, M. and Brunner, H.R. eds. Hanley and Belfus, Inc.: Philadelphia, PA. pp. 257-261.				
	184.	Ford, E.S. et al. (2002). "Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey," <i>JAMA</i> 287(3):356-359.				
	185.	Galvin, P. et al. (1992). "A Simple Method for Quantitation of Insulin Sensitivity and Insulin Release From an Intravenous Glucose Tolerance Test," <i>Diabetic Medicine</i> 9:921-928.				
	186.	Groff, J.L. et al. (1993). "Simplified Enzymatic Assay of Angiotensin-Converting Enzyme in Serum," <i>Clin. Chem.</i> 39(3):400-404.				
	187.	Hansson, L. et al. (1999). "Effect of Angiotensin-Converting-Enzyme Inhibition Compared with Conventional Therapy on Cardiovascular Morbidity and Mortality in Hypertension: The Captopril Prevention Project (CAPPP) Randomised Trial," <i>The Lancet</i> 353:611-616.				
	188.	Henke, B.R. et al. (1998). "N-(2-Benzoylphenyl)-L-Tyrosine PPARγ Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents," J. Med. Chem. 41:5020-5036.				
	189.	Henriksen, E.J. et al. (2001). "Selective Angiotensin II Receptor Antagonism Reduces Insulin Resistance in Obese Zucker Rats," <i>Hypertension</i> 38:884-890.				
	190.	Horiuchi, M. et al. (2003). "Fluvastatin Enhances the Inhibitory Effects of a Selective Angiotensin II Type 1 Receptor Blocker, Valsartan, on Vascular Neointimal Formation," <i>Circulation</i> 107:106-112.				
	191.	Janke, J. et al. (2002). "Mature Adipocytes Inhibit In Vitro Differentiation of Human Preadipocytes Via Angiotensin Type 1 Receptors," <i>Diabetes</i> 51:1699-1707.				
	192.	Katsuki, A. et al. (2001). "Homeostasis Model Assessment Is a Reliable Indicator of Insulin Resistance During Follow-up of Patients With Type 2 Diabetes," <i>Diabetes Care</i> 24(2):362-365.				
	193.	Kubo, K. et al. (1993). "Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Benzimidazoles," <i>J. Med. Chem.</i> 36:1772-1784.				
	194.	Laaksonen, D.E. et al. (2002). "Metabolic Syndrome and Development of Diabetes Mellitus: Application and Validation of Recently Suggested Definitions of the Metabolic Syndrome in a Prospective Cohort Study," <i>American Journal of Epidemiology</i> 156(11):1070-1077.				
	195.	Le Bourdonnec, B. et al. (2000). "Synthesis and Pharmacological Evaluation of New Pyrazolidine-3, 5-diones as AT ₁ Receptor Antagonists," <i>J. Med. Chem.</i> 43:2685-2697.				
	196.	Le Bourdonnec, B. et al. (2002). "Comparison of 3D Structures and AT ₁ Binding Properties of Pyrazolidine-3,5-diones and Tetrahydropyridazine-3,6-diones with Parent Antihypertensive Drug Irbesartan," <i>J. Med. Chem.</i> 45:4794-4798.				
	197.	Lin, H.S. et al. (1992). "Nonpeptide Angiotensin II Receptor Antagonists: Synthetic and Computational Chemistry of N-[[4-(2H-Tetrazol-5-yl)-1-Cycloalken-1-yl]Phenyl]Methyl]Imidazole Derivatives and Their In Vitro Activity," J. Med. Chem. 35:2658-2667.				
EXAMI	NER:		DATE CONSIDERED:			

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92) pa- 820933

Form PTO-1449)	Docket Number 421842000400	Application Number 10/627,372		
/ / \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	TION DISCLOSURE CITATION N AN APPLICATION	Applicant Harrihar A. PERSHADSINGH			
F	(Use several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned		
NOV 2 4 2003 😹		Mailing Date November 21, 2003			
TAUE 198.					
198.	Maillard, M.P. et al. (2002). "Pharmac Receptor Blockade in Healthy Volunto 71(1):68-76.				
199.	Mederski, W.W. K.R. et al. (1994). "Non-Peptide Angiotensin II Receptor Antagonists: Synthesis and Biological Activity of a Series of Novel 4,5-Dihydro-4-oxo-3 <i>H</i> -imidazo(4,5- <i>c</i>)pyridine Derivatives," <i>J. Med. Chem.</i> 37:1632-1645.				
200.	Meigs, J.B. et al. (2003). "The Natural History of Progression From Normal Glucose Tolerance to Type 2 Diabetes in the Baltimore Longitudinal Study of Aging," <i>Diabetes</i> 52:1475-1484				
201.	Miyajima, A. et al. (2002). "Angiotensin II Type I Antagonist Prevents Pulmonary Metastasis of Murine Renal Cancer by Inhibiting Tumor Angiogensis," <i>Cancer Res.</i> 62:4176-4179.				
202.	Miyazaki, M. et al. (1999). "Angiotensin II Type I Receptor Antagonist, TCV-116, Prevents Neointima Formation in Injured Arteries in the Dog," <i>Jpn. J. Pharmacol.</i> 79:455-460.				
203.	Nelson, K.A. et al. (1994). "The Cancer Anorexia-Cachexia Syndrome," Journal of Clinical Oncology 12(1):213-225.				
204.	Norman, M.H. et al. (1995). "4-(Heteroarylthio)-2-biphenylyltetrazoles as Nonpeptide Angiotensin II Antagonists," J. Med. Chem. 38:4670-4778.				
205.	Phillips, M.I. and Kagiyama, S. (2002). "Angiotensin II As A Pro-Inflammatory Mediator," <i>Curr. Opin. Investig. Drugs</i> 3(4):569-577.				
206.	Sasaki, K. et al. (2002). "Evidence for the Importance of Angiotensin II Type 1 Receptor in Ischemia-Induced Angiogenesis," <i>J. Clin. Invest.</i> 109:603-611.				
207.	Schmidt, B. and Schieffer, B. (2003). "Angiotensin II AT1 Receptor Antagonists. Clinical Implications of Active Metabolites," <i>J. Med. Chem.</i> 46(12):2261-2270.				
208.	Sharma, A.M. et al. (2002). "Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells," <i>Hypertension</i> 40:609-611.				
209.	Shiuchi, T. et al. (2002). "ACE Inhibitor Improves Insulin Resistance in Diabetic Mouse via Bradykinin and NO," <i>Hypertension</i> 40:329-334.				
210.	Silvestre, J.S. et al. (2002). "Antiangiogenic Effect of Angiotensin II Type 2 Receptor in Ischemia-Induced Angiogenesis in Mice Hindlimb," <i>Circ. Res.</i> 90:1072-1079.				
211.	Smith, K.L. and Tisdale, M.J. (1993). "Mechanism of Muscle Protein Degradation in Cancer Cachexia," <i>British Journal of Cancer</i> 68:314-318.				
212.	Tamarat, R. et al. (2002). "Angiotensin II Angiogenic Effect in Vivo Involves Vascular Endothelial Growth Factor- and Inflammation-Related Pathways," <i>Lab. Invest.</i> 82(6):747-756.				
213.	Tanaka, Y. et al. (1989). "Antitumor Activity of Indomethacin in Mice Bearing Advanced Colon 26 Carcinoma Compared with Those with Early Transplants," <i>Cancer Research</i> 49:5935-5939.				
EXAMINER:		DATE CONSIDERED:			
	itial if citation considered, whether or not the citati not considered. Include a copy of this form with i		line through the citation if not in		

Form PTO-1449		Docket Number 421842000400	Application Number 10/627,372	
y 4 5 4 7 4 1	ION DISCLOSURE CITATION AN APPLICATION	Applicant Harrihar A. PERSHADSINGH		
unv 2 4 2003	Use several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned	
mui -		Mailing Date November 21, 2003		
PADEMARK 214				
214.	Teuscher, A.U. and Weidmann, P.U. (1997). "Requirements for Antihypertensive Therapy in Diabetic Patients: Metabolic Aspects," <i>Journal of Hypertension</i> 15(Supp. 2):S67-S75.			
215.	Tham, D.M. et al. (2002). "Angiotensin II Is Associated With Activation of NF-κB-Mediated Genes and Downregulation of PPARs," <i>Physiol. Genomics</i> 11:21-30.			
216.	Tomiyama, H. et al. (1994). "Kinins Contribute to the Improvement of Insulin Sensitivity During Treatment with Angiotensin Converting Enzyme Inhibitor," <i>Hypertension</i> 23:450-455.			
217.	Wang, N. et al. (2002). "Constitutive Activation of Peroxisome Proliferator-Activated Receptor-γ Suppresses Pro-Inflammatory Adhesion Molecules in Human Vascular Endothelial Cells," <i>J. Biol. Chem.</i> 277(37):34176-34181.			
218.	Yusuf, S. et al. (2001). "Ramipril and the Development of Diabetes," JAMA 286:1882-1885.			
219.	Zimmet, P. et al. (2001). "Global and Societal Implications of the Diabetes Epidemic," <i>Nature</i> 414:782-787.			

EXA	MIN	ER:
-----	-----	-----

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.